Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9

Neuro Oncol. 2019 Dec 17;21(12):1607-1609. doi: 10.1093/neuonc/noz145.

Hans-Georg Wirsching^{1

2}, Sonali Arora^{1

3}, Huajia Zhang⁴, Frank Szulzewsky¹, Patrick J Cimino^{1

5}, Christophe Quéva⁶, A McGarry Houghton⁴, Joseph C Glorioso⁷, Michael Weller², Eric C Holland^{1

4

8

9}

¹ Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
² Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
³ Seattle Translational Tumor Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁴ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁵ Department of Pathology, Division of Neuropathology, University of Washington, Seattle, Washington, USA.
⁶ Oncorus Inc, Cambridge, Massachusetts, USA.
⁷ Department of Microbiology and Molecular Genetics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
⁸ Department of Neurosurgery, University of Washington, Seattle, Washington, USA.
⁹ Alvord Brain Tumor Center, University of Washington, Seattle, Washington, USA.

No abstract available

Publication types